Another embodiment of the invention relates to a phar maceutical composition comprising the succinate salt of 11.04 5,8,14-triazatetracyclo[l0.3.l .02 9 ]-hexadeca-2(11 ),3, • • 5,7,9-pentaene and a pharmaceutically acceptable carrier or excipient, particularly, one for use in the treatment of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (eq., depen dencies on, or addictions to nicotine (and/or tobacco 55 products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TEI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related 60 cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.

The present invention further relates to a the method of treating inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.q., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TEI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzhe imer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome comprises administering to a subject in need of treatment a therapeutically effective amount of the succinate salt of 11 .04 5,8,14-triazatetracyclo[l0.3.

Another more preferred embodiment of the invention relates to a method of treatment for nicotine dependency, addiction and withdrawal, in particular for use in smoking cessation therapy activity, comprising the administration of the succinate salt of 5,8,14-triazatetracyclo 11 .04 [10.3.1.02 9 ]-hexadeca-2(11),3,5,7,9-pentaene to a sub- 30 • • ject in need thereof.

Variations 40 may nevertheless occur depending upon the weight and condition of the persons being treated and their individual responses to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval during which such administration is carried out.

Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar, as well as 10 high molecular weight polyethylene glycols.

While examples exist in the art suggesting that CR dosage forms may in some cases provide for a reduction in such side effects as nausea (e.g., oxycodone (J, R. Caldwell, et al., J. of Rheumatology.1999, 26, 862-869), venlafaxine (R. Entsuah and R. Chitra, Psychopharmaco/ogy Bulletin, 1997, 33, 671-676) and paroxetine (R. N. Golden, et al., J. Cl/n.

Although consideration of the chemical structure and identification of reactive moieties therein can be used to theorize potential degradation pathways, it remains impossible to predict a priori whether a particular excipient will form an acceptably stable formulation with a given drug.

certainly provide for the benefits described in the present Invention, the inventors have found that to achieve the desired therapeutic blood levels while maintaining the nausea reduction, the drug is administered at a rate of between about 0.06 and 3 mgAlhr; and more preferably between 0.1 and 1 mgA/hr.

Suitable salt derivatives Include halides, thiocyanates, sulfates, bisulfates, sulfites, phosphonates, monohydrogen-phosphates, alkylsulfates, arylsulfonates, bisulfltes, alkanoates, pyrophosphonates, metaphosphates, dihydrogenphosphates, · cycloalkylalkanoates, arylalkonates, adipates, alginates, aspartates, benzoates, fumarates, glucoheptanoates, glycerophosphates, lactates, maleates, nicotinates, oxalates, palmitates, camphorates, citrates, tartarates, succlnates, pivalates, picrates, pectinates, camphorsulfonates, digluconates, trifluoroacetates, and the like.

ranu a Ing gen It' A lsoproovl 5.70 o 260.20 q - 333.30 a 333.30 Cl - 50.00 !l - 533.30 o s.ooa 12.50 a 5.70 a 255.20 a 333.30 a - 333.30 o 10.00 g 50.00 g 533.30 o - 5.00 !l 7.50 !l The Inactive Ingredients listed above the granulating agent (water or isopropyl alcohol) in the formulation table were added to a high shear blender and dry mixed for 1 minute at 100 rpm impeller speed.